礼来公司(Eli Lilly)近日通过联合声明宣布,其创新药物米利珠单抗(Mirikizumab)已正式获得中国监管机构批准,用于治疗中重度克罗恩病及溃疡性结肠炎。这一重要进展为国内相关患者提供了新的治疗选择,标志着礼来在免疫疾病领域布局的进一步深化。
礼来公司(Eli Lilly)近日通过联合声明宣布,其创新药物米利珠单抗(Mirikizumab)已正式获得中国监管机构批准,用于治疗中重度克罗恩病及溃疡性结肠炎。这一重要进展为国内相关患者提供了新的治疗选择,标志着礼来在免疫疾病领域布局的进一步深化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.